


patent application as follows:

Amendments to the Claims

1-16. (Cancelled)

17. (Currently amended) A compound represented by the structural formula:



wherein

R₁ is hydrogen;

C₁₋₁₀ alkyl or substituted alkyl;

;O(CH₂)_n-Y

N(COZ)(CH₂)_mY; or

N[(CH₂)_mQ][(CH₂)_nY];

R₂ and R₃ are independently selected from:

hydrogen;

C₁₋₁₀ alkyl or substituted alkyl; or

R₂ and R₃ together are cycloalkyl;

R₄ is hydrogen;

C₁₋₁₀ alkyl or substituted alkyl;

phenyl or substituted phenyl;

(CH₂)_nY; or

(CH₂)_mO(CH₂)_nY;

wherein:

m and n are independently between 1 and 10;

Q and Y are independently selected from


hydrogen, CO₂H or salts thereof or OPO₃²⁻;

Z is hydrogen or C₁₋₁₀ alkyl or substituted alkyl;

and,

X ~~is~~ represents an amino acid, ~~a peptide,~~
~~oligopeptide or polypeptide.~~

18. (Currently amended) A compound represented by the structural formula:



wherein

R₂ and R₃ are independently selected from hydrogen, C₁₋₁₀ alkyl or substituted alkyl, or R₂ and R₃ together are cycloalkyl;

R₄' is a blocking group; and,

X ~~is~~ represents an amino acid, ~~a peptide,~~
~~oligopeptide or polypeptide.~~

19. (Previously amended) The compound of claim 18,


wherein R₄' is selected from:

hydrogen;

C₁₋₁₀ alkyl or substituted alkyl;

phenyl or substituted phenyl;

(CH₂)_nCO₂Y; and,



wherein:

m and n are independently between 0 and 10; and,

Y is hydrogen, or C₁₋₁₀ alkyl or substituted

alkyl.

20. (Currently amended) The compound of claim 17, or a salt thereof, wherein the compound is:

~~Methyl 1-glutaryl-7-nitroindoline-5-acetate 8;~~

~~Methyl 1-[(5-dihydroxyphosphoryloxy)pentanoyl]-~~

~~7-nitroindoline-5-acetate 9;~~

Methyl 1-[S-(4-amino-4-carboxybutanoyl)]-7-

nitroindoline-5-acetate 10;

Methyl 1-(4-aminobutanoyl)-7-nitroindoline-5-

acetate 21;

~~Methyl 1-acetyl-7-nitroindoline-5-acetate 16;~~

~~Mono[1-(5-methoxycarbonylmethyl-7-nitroindolyl)]~~

~~amide of 1,2-bis(0-aminophenoxy)ethane~~

~~N,N,N',N'-tetraacetic acid;~~

~~1-Acetyl-4-methoxy-7-nitroindoline 25;~~

~~1-Acetyl-4-methoxy-5-methy-7-nitroindoline 30;~~

1-[S-(4-Amino-4-carboxybutanoyl)]-4-methoxy-7-

nitroindoline;

1-(4-Aminobutanoyl)-4-methoxy-7-nitroindoline;

~~1-[(5-Dihydroxyphosphoryloxy)pentanoyl]-4-~~

~~methoxy-7-nitroindoline;~~

1-[S-(4-Amino-4-carboxybutanoyl)]-4-methoxy-5-

methyl-7-nitroindoline; or

1-(4-Aminobutanoyl)-4-methoxy-5-methyl-7-nitroindoline, ~~or~~

~~1-[(5-Dihydroxyphosphoryloxy)pentanoyl]-4-methoxy-5-methyl-7-nitroindoline.~~

21. (Currently amended) The compound of claim 18, or a salt thereof, wherein the compound is:

~~Methyl 1-glutaryl-7-nitroindoline-5-acetate 8;~~

~~Methyl 1-[(5-dihydroxyphosphoryloxy)pentanoyl]-7-nitroindoline-5-acetate 9;~~

Methyl 1-[*S*-(4-amino-4-carboxybutanoyl)]-7-nitroindoline-5-acetate 10;

Methyl 1-(4-aminobutanoyl)-7-nitroindoline-5-acetate 21;

~~Methyl 1-acetyl-7-nitroindoline-5-acetate 16;~~

~~Mono[1-(5-methoxycarbonylmethyl-7-nitroindolyl)] amide of 1,2-bis(0-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid;~~

~~1-Acetyl-4-methoxy-7-nitroindoline 25;~~

~~1-Acetyl-4-methoxy-5-methyl-7-nitroindoline 30;~~

1-[*S*-(4-Amino-4-carboxybutanoyl)]-4-methoxy-7-nitroindoline;

1-(4-Aminobutanoyl)-4-methoxy-7-nitroindoline;

~~1-[(5-Dihydroxyphosphoryloxy)pentanoyl]-4-methoxy-7-nitroindoline;~~

1-[*S*-(4-Amino-4-carboxybutanoyl)]-4-methoxy-5-methyl-7-nitroindoline; or

1-(4-Aminobutanoyl)-4-methoxy-5-methyl-7-

nitroindoline, ~~or~~

~~1-[(5-Dihydroxyphosphoryloxy)pentanoyl]-4-~~

~~methoxy-5-methyl-7-nitroindoline.~~

22. (Previously added) The compound of claim 17, wherein X represents a neuroactive amino acid selected from the group of L-glutamate, GABA or glycine.
23. (Previously added) The compound of claim 18, wherein X represents a neuroactive amino acid selected from the group of L-glutamate, GABA or glycine.
24. ~~(New) The compound of claim 17, wherein X represents a peptide selected from the group of thyrotrophin releasing hormone, an enkephalin, bradykinin or angiotensin II.~~
25. ~~(New) The compound of claim 18, wherein X represents a peptide selected from the group of thyrotrophin releasing hormone, an enkephalin, bradykinin or angiotensin II.~~
26. (Currently amended) A composition comprising a compound of claim 17 and a pharmaceutically acceptable excipient or carrier.
27. (Currently amended) A composition comprising a compound of claim 18 and a pharmaceutically acceptable excipient or carrier.
28. (Currently amended) A composition comprising a compound of claim 19 and a pharmaceutically acceptable excipient or carrier.

29. (Currently amended) A composition comprising a compound of claim 20 and a pharmaceutically acceptable excipient or carrier.
30. (Currently amended) A composition comprising a compound of claim 21 and a pharmaceutically acceptable excipient or carrier.
31. (Withdrawn) A process for releasing an amino acid, a peptide or polypeptide, the process comprising irradiating a photoreleasable compound of claim 17 to cause the release of the amino acid, neuroactive amino acid, peptide, oligopeptide or polypeptide.
32. (Withdrawn) The process of claim 31, wherein said amino acid comprises a neuroactive amino acid.
33. (Withdrawn) A process for releasing an amino acid, a neuroactive amino acid, a peptide or polypeptide, the process comprising irradiating a photoreleasable compound of claim 18 to cause the release of the amino acid, peptide, oligopeptide or polypeptide.
34. (Withdrawn) The process of claim 33, wherein said amino acid comprises a neuroactive amino acid.
35. (Withdrawn) A process for releasing an amino acid, a neuroactive amino acid, a peptide or polypeptide, the process comprising irradiating a photoreleasable compound of claim 19 to cause the release of the amino acid, neuroactive amino acid, peptide, oligopeptide or polypeptide.

36. (Withdrawn) The process of claim 35, wherein said amino acid comprises a neuroactive amino acid.
37. (Withdrawn) A process for releasing an amino acid, a neuroactive amino acid, a peptide or polypeptide, the process comprising irradiating a photoreleasable compound of claim 20 to cause the release of the amino acid, neuroactive amino acid, peptide, oligopeptide or polypeptide.
38. (Withdrawn) The process of claim 37, wherein said amino acid comprises a neuroactive amino acid.
39. (Withdrawn) A process for releasing an amino acid, a neuroactive amino acid, a peptide or polypeptide, the process comprising irradiating a photoreleasable compound of claim 21 to cause the release of the amino acid, neuroactive amino acid, peptide, oligopeptide or polypeptide.
40. (Withdrawn) The process of claim 39, wherein said amino acid comprises a neuroactive amino acid.
41. (Withdrawn) A process of producing a compound of claim 17, the process comprising:
- (a) reacting indoline or a derivatized indoline to substitute a blocking group at the 5-position;
 - (b) reacting the indoline compound of step (a) to couple an effector moiety at the heterocyclic nitrogen, the effector group having a protecting group; and,

- (c) nitrating the indoline compound of step (b) at the 7-position to produce said compound.
- 42. (Withdrawn) A process for purifying a compound of claim 17, the process comprising:
 - (a) eluting the compound from a HPLC column using aqueous methanol containing buffer salts;
 - (b) desalting fractions containing the compound obtained from step (a) on Amberlite XAD-2™ resin; and,
 - (c) eluting the resin with methanol to recover the compound.
- 43. (New) The compound of claim 17, wherein said amino acid is a neuroactive amino acid.
- 44. (New) The compound of claim 18, wherein said amino acid is a neuroactive amino acid.
- 45. (New) The compound of claim 19, wherein said amino acid is a neuroactive amino acid.
- 46. (New) A composition comprising a compound of claim 43 and a pharmaceutically acceptable excipient or carrier.
- 47. (New) A composition comprising a compound of claim 44 and a pharmaceutically acceptable excipient or carrier.
- 48. (New) A composition comprising a compound of claim 45 and a pharmaceutically acceptable excipient or carrier.